MyFinsight
Home
Blog
About
Contact
Download
Download image
Marketable securities
$120,795,235
Cash and cash
equivalents
$49,573,510
Prepaid expenses and
other current assets
$1,292,813
Prepaid research and
development
$514,910
Total current assets
$172,176,468
Prepaid research and
development, noncurrent
$1,000,000
Other assets
$155,759
Total assets
$173,332,227
Total liabilities and
stockholders' equity
$173,332,227
Total stockholders'
equity
$167,620,268
Total liabilities
$5,711,959
Accumulated deficit
-$159,060,640
Accumulated other
comprehensive income (loss)
-$26,293
Additional paid-in capital
$326,575,169
Total current
liabilities
$5,711,959
Common stock, 0.001 par
value 500,000,000 and...
$132,032
Accrued expenses and
other current...
$4,124,654
Accounts payable
$1,587,305
Back
Back
Balance Sheet
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)
source: myfinsight.com